80 reports

  • GENETIC DISORDERS, COMMON SYMPTOMS OF GENETIC DISORDERS
  • GENETIC DISORDERS, PROGRESSION OF CF

Global Genetic Disorders Drugs Market to 2023 - A Rapidly Growing Treatment Landscape Driven by Targeted Complement System Inhibitors and Enzyme Replacement Therapies to Treat PNH and Lysosomal Storage Disease Summary Genetic disorders are caused by abnormalities in a person’s genome and represent...

  • Genetic Disorder
  • World
  • Market Size
  • Alexion Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.

Global Genetic disorders Partnering 2012-2018: Deal trends, players and financials Executive Summary Chapter ## – Introduction Chapter ## – Trends in Genetic Disorders dealmaking ##. ##.

  • Genetic Disorder
  • Pathology
  • World
  • Demand
  • Genetic diseases
  • Non-genetic diseases

About Prenatal DNA Sequencing Prenatal DNA sequencing is the method of DNA sequencing where DNA isolated from the blood of pregnant women to reveal the full genetic code of a fetus. It is useful in detecting disorders such as Down syndrome, cystic fibrosis, thalassemia, and cancer. Technavio’s analysts forecast...

  • Genetic Disorder
  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Natera, Inc.

2018 Japan Nucleic Acid Testing/ NAT Market: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing Highlights Comprehensive ##, ##-page market segmentation analysis of the Japanese NAT

  • Genetic Disorder
  • Pathology
  • Japan
  • Demand
  • Forecast

Nucleic Acid Testing/ NAT Market: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing Highlights Comprehensive ##, ##-page market segmentation analysis of the US NAT market.

  • Genetic Disorder
  • Pathology
  • United States
  • Demand
  • Forecast

Nucleic Acid Testing/ NAT Market: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing Highlights Comprehensive ##, ##-page market segmentation analysis of the UK NAT market.

  • Genetic Disorder
  • Pathology
  • United Kingdom
  • Demand
  • Forecast

2018 Germany Nucleic Acid Testing/ NAT Market: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing Highlights Comprehensive ##, ##-page market segmentation analysis of the German NA

  • Genetic Disorder
  • Pathology
  • Germany
  • Demand
  • Forecast

2018 Italy Nucleic Acid Testing/ NAT Market: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing Highlights Comprehensive ##, ##-page market segmentation analysis of the Italian NAT

  • Genetic Disorder
  • Pathology
  • Italy
  • Demand
  • Forecast

2018 Spain Nucleic Acid Testing/ NAT Market: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing Highlights Comprehensive ##, ##-page market segmentation analysis of the Spanish NAT

  • Genetic Disorder
  • Pathology
  • Spain
  • Demand
  • Forecast

Ten-year test volume and reagent sales forecasts for the following categories: & nbsp; & nbsp; & nbsp; - & nbsp; Infectious Diseases Genetic Diseases & nbsp; & nbsp; & nbsp; - & nbsp; Cancer & nbsp; & nbsp; & nbsp; - & nbsp; Paternity Testing/

  • Genetic Disorder
  • Molecular Diagnostic
  • Spain
  • Demand
  • Forecast
  • JAPAN - CYSTIC FIBROSIS THERAPEUTICS MARKET (MILLION US$), 2014 - 2016
  • 6.2 CANADA CYSTIC FIBROSIS THERAPEUTICS MARKET & FORECAST

The market for Cystic Fibrosis Therapeutics is anticipated to grow with double digit CAGR during the forecasting period. Cystic fibrosis is among the most common life-threatening genetic disorders worldwide. It is caused by defects in a single gene known as the cystic fibrosis transmembrane conductance regulator, or CFTR. The increasing...

  • Genetic Disorder
  • World
  • Market Size
  • AbbVie Inc.
  • Editas Medicine, Inc.
  • GLOBAL CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 & 2022
  • 5 Cystic Fibrosis Market, By Treatment Method

Cystic fibrosis is a genetic disease.

  • Genetic Disorder
  • AbbVie Inc.
  • Allergan plc
  • Pharmaxis Ltd
  • Vertex Pharmaceuticals Incorporated
  • 5 Cystic Fibrosis Market, By Treatment Method
  • GLOBAL CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 & 2022

Cystic fibrosis is a genetic disease.

  • Genetic Disorder
  • AbbVie Inc.
  • Allergan plc
  • Pharmaxis Ltd
  • Vertex Pharmaceuticals Incorporated
  • Carrier Screening Market: Revenue in USD million, by Disease Type, Global, 2018-2023
  • 4. KEY INFERENCES

The global carrier screening market is expected to account for a value of USD 2,237 million, registering a CAGR of about 9.8% during the forecast period (2018-2023). Carrier screening is one of the genetic tests that provide the data on whether a particular person carries a gene for certain genetic disorders or not. When the test is performed...

  • Genetic Disorder
  • 23andMe, Inc.
  • Cepheid
  • Illumina, Inc.
  • Sequenom, Inc.
  • Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders
  • Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2015 Summary GlobalData's clinical trial report, “Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2015" provides an overview of Adrenoleukodystrophy (Adrenomyeloneuropathy/...

  • Genetic Disorder
  • World
  • Aldagen, Inc.
  • Asklepion Pharmaceuticals, LLC
  • Nutra Pharma Corporation
  • Clinical Trials by G7 Countries: Proportion of Primary Immune Deficiency (PID) to Genetic Disorders Clinical Trials
  • Clinical Trials by E7 Countries: Proportion of Primary Immune Deficiency (PID) to Genetic Disorders Clinical Trials

Primary Immune Deficiency (PID) Global Clinical Trials Review, H2, 2015 Summary GlobalData's clinical trial report, “Primary Immune Deficiency (PID) Global Clinical Trials Review, H2, 2015" provides an overview of Primary Immune Deficiency (PID) clinical trials scenario. This report provides top line data relating to the...

  • Genetic Disorder
  • World
  • Baxter International Inc.
  • Biotest AG
  • CSL Limited

GENETIC FACTORS ARE ALSO A CONTRIBUTOR TO IPF; AROUND ## IN ## PEOPLE WITH IPF HAVE ANOTHER FAMILY MEMBER WITH THE DISEASE DUE TO A DISEASE CALLED FAMILIAL IDIOPATHIC FIBROSIS.

  • Genetic Disorder
  • World
  • Market Size
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • II. Etiology and Genetics of Cystic Fibrosis
  • 1. CYSTIC FIBROSIS: DISEASE OVERVIEW

Cystic fibrosis is a rare genetic disorder caused by the mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene located on chromosome 7. It largely affects the lungs and digestive system, and causes the secretions to become thick and sticky. The individuals with cystic fibrosis develop lung disease, resulting...

  • Cystic Fibrosis
  • Genetic Disorder
  • World
  • AbbVie Inc.
  • Vertex Pharmaceuticals Incorporated
  • PULMONARY HYPERTENSION

Engages in the development of drugs in areas such as immuno-oncology, oncology, immunoscience, virology, cardiovascular, fibrotic diseases, and metabolic and genetically defined diseases.

  • Genetic Disorder
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG

(USA) ##.

  • Genetic Disorder
  • Pharmaceutical
  • China
  • World
  • Market Shares
  • INTRODUCTION

IT IS AN AUTOSOMAL RECESSIVE GENETIC disorder caused by mutations in the CF gene.

  • Genetic Disorder
  • North America
  • United States
  • AstraZeneca PLC
  • Novartis AG
  • Snapshot of Cystic Fibrosis
  • 06. Introduction

About Cystic Fibrosis Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited disease. The primary symptoms of cystic fibrosis include high salt content in the sweat, breathing difficulties, secretion of abnormally viscous mucus, respiratory complications, difficulties related to digestion, and growth anomalies. Cystic...

  • Genetic Disorder
  • Europe
  • Actavis plc
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.

Cystic fibrosis and bone disease: are we missing a genetic link?

  • Genetic Disorder
  • Canada
  • France
  • Italy
  • Forecast

Cystic fibrosis and bone disease: are we missing a genetic link?

  • Genetic Disorder
  • Forest Laboratories, Inc.
  • Novartis AG
  • Pharmaxis Ltd
  • Vertex Pharmaceuticals Incorporated
  • PROPORTION OF OSTEOGENESIS IMPERFECTA TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • Proportion of Osteogenesis Imperfecta to Genetic Disorders Clinical Trials, G7 Countries (%), 2015*

Osteogenesis Imperfecta Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Osteogenesis Imperfecta Global Clinical Trials Review, H1, 2018" provides an overview of Osteogenesis Imperfecta clinical trials scenario.This report provides top line data relating to the...

  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • Mereo Biopharma Group Limited
  • PROPORTION OF NEUROFIBROMATOSES TYPE I (VON RECKLINGHAUSEN'S DISEASE) TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2018*
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF NEUROFIBROMATOSES TYPE I (VON RECKLINGHAUSEN'S DISEASE) TO GENETIC DISORDERS CLINICAL TRIALS

Neurofibromatoses Type I (Von Recklinghausen’s Disease) Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Neurofibromatoses Type I (Von Recklinghausen’s Disease) Global Clinical Trials Review, H1, 2018" provides an overview of Neurofibromatoses Type I (Von Recklinghausen’s...

  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • AstraZeneca PLC
  • PROPORTION OF NEUROFIBROMATOSES TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2018*
  • CLINICAL TRIALS BY E7 COUNTRIES: PROPORTION OF NEUROFIBROMATOSES TO GENETIC DISORDERS CLINICAL TRIALS

Neurofibromatoses Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Neurofibromatoses Global Clinical Trials Review, H1, 2018" provides an overview of Neurofibromatoses clinical trials scenario.This report provides top line data relating to the clinical trials on...

  • Clinical Trial
  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • PREVALENCE OF GENETIC DISORDERS (2012)
  • 8.2 GENETIC DISORDERS

The molecular cytogenetics market is projected to reach USD 2.52 billion by 2021 from USD 1.55 billion in 2016, at a CAGR of 10.1% from 2016 to 2021. The global molecular cytogenetics market is segmented based on product, technique, application, end user, and region. The kits and reagents segment is expected to register the highest growth...

  • Cytogenetic
  • Genetic Disorder
  • United States
  • Market Size
  • Agilent Technologies, Inc.
  • PROPORTION OF DOWN SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • PROPORTION OF DOWN SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2017*

Down Syndrome Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Down Syndrome Global Clinical Trials Review, H2, 2017" provides an overview of Down Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Down Syndrome. Report includes...

  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • F. Hoffmann-La Roche Ltd.
  • PROPORTION OF MUCKLE-WELLS SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • CLINICAL TRIALS BY E7 COUNTRIES: PROPORTION OF MUCKLE-WELLS SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS

Muckle-Wells Syndrome Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Muckle-Wells Syndrome Global Clinical Trials Review, H2, 2017" provides an overview of Muckle-Wells Syndrome clinical trials scenario. This report provides top line data relating to the clinical...

  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • Novartis AG